Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer

Gastric Cancer

Volumn 3, Issue 3, 2000, Pages 128-133

  Yoshida, Shigeaki ^a   Miyata, Yoshinori ^b   Ohtsu, Atsushi ^a   Boku, Narikazu ^a   Shirao, Kuniaki ^c   Shimada, Yasuhiro ^c  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Gastric cancer; Japanese criteria; RECIST; Response outcomes; WHO criteria

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; MITOMYCIN C; UFT;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG RESPONSE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

EID: 0034484031     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00011706     Document Type: Article

References (8)

1. New guidelines to evaluate the response to treatment in solid tumors
2. Phase III study of UFT + MMC versus 5-FU + CDDP versus 5-FU alone in patients with advanced gastric cancer: JCOG study 9205. Proc ASCO 1043
3. Evaluation of the effect of chemotherapy in gastric cancer patients with an intact primary tumor according to criteria of the Japanese Research Society for Gastric Cancer
4. Response of the primary lesion in gastric cancer to chemotherapeutic trials
5. Advantage of Japanese response criteria for estimating the survival of patients with primary gastric cancer
6. Measuring response in solid tumors: Unidimensional versus bidimensional measurement